Gufic Biosciences Limited · NSE: GUFICBIO · BSE: 509079

Gufic Biosciences

Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 14 Aug 2026.

Q1 FY27 · Consolidated

Revenue
260.82₹ Cr
+16.6% vs year ago
Net profit
22.31₹ Cr
+70.7% vs year ago
EPS, basic
2.22₹
+70.8% vs year ago
Net margin
8.6%
+2.7 pts vs year ago
Revenue₹ crore · consolidated · last 12 quarters
Q2 FY24: ₹214.87 CrQ3 FY24: ₹201.78 CrQ4 FY24: ₹194.99 CrQ1 FY25: ₹202.81 CrQ2 FY25: ₹204.18 CrQ3 FY25: ₹207.79 CrQ4 FY25: ₹205.02 CrQ1 FY26: ₹223.72 CrQ2 FY26: ₹237.05 CrQ3 FY26: ₹231.41 CrQ4 FY26: ₹251.82 CrQ1 FY27: ₹260.82 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27
Net profit₹ crore · consolidated · last 12 quarters
Q2 FY24: ₹23.21 CrQ3 FY24: ₹22.26 CrQ4 FY24: ₹20.05 CrQ1 FY25: ₹20.86 CrQ2 FY25: ₹21.77 CrQ3 FY25: ₹19.31 CrQ4 FY25: ₹7.72 CrQ1 FY26: ₹13.07 CrQ2 FY26: ₹16.82 CrQ3 FY26: ₹12.42 CrQ4 FY26: ₹21.90 CrQ1 FY27: ₹22.31 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27

Quarter by quarter

Consolidated · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 2026260.82+16.6%22.31+70.7%2.2214 Aug 2026
Q4 FY26Jan–Mar 2026251.82+22.8%21.90+183.6%2.1829 May 2026
Q3 FY26Oct–Dec 2025231.41+11.4%12.42−35.6%1.2413 Feb 2026
Q2 FY26Jul–Sep 2025237.05+16.1%16.82−22.7%1.6814 Nov 2025
Q1 FY26Apr–Jun 2025223.72+10.3%13.07−37.3%1.3013 Aug 2025
Q4 FY25Jan–Mar 2025205.02+5.1%7.72−61.5%0.7730 May 2025
Q3 FY25Oct–Dec 2024207.79+3.0%19.31−13.3%1.9314 Feb 2025
Q2 FY25Jul–Sep 2024204.18−5.0%21.77−6.2%2.1715 Nov 2024
Q1 FY25Apr–Jun 2024202.81—20.86—2.0829 Aug 2024
Q4 FY24Jan–Mar 2024194.99—20.05—2.0011 Jun 2024
Q3 FY24Oct–Dec 2023201.78—22.26—2.2326 Feb 2024
Q2 FY24Jul–Sep 2023214.87—23.21—2.3922 Nov 2023
Standalone results
Standalone · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 2026260.82+14.9%22.46+86.0%2.2414 Aug 2026
Q4 FY26Jan–Mar 2026252.05+22.9%20.57+158.0%2.0529 May 2026
Q3 FY26Oct–Dec 2025231.09+11.2%15.56−19.5%1.5513 Feb 2026
Q2 FY26Jul–Sep 2025230.42+12.9%14.94−31.4%1.4914 Nov 2025
Q1 FY26Apr–Jun 2025226.91+11.9%12.07−42.1%1.2013 Aug 2025
Q4 FY25Jan–Mar 2025205.02+5.1%7.97−60.2%0.8030 May 2025
Q3 FY25Oct–Dec 2024207.79+3.0%19.32−13.2%1.9314 Feb 2025
Q2 FY25Jul–Sep 2024204.18−5.0%21.78−6.2%2.1715 Nov 2024
Q1 FY25Apr–Jun 2024202.81+4.0%20.86+1.1%2.0829 Aug 2024
Q4 FY24Jan–Mar 2024194.99+12.7%20.05+10.7%2.0011 Jun 2024
Q3 FY24Oct–Dec 2023201.78+13.7%22.26+9.4%2.2326 Feb 2024
Q2 FY24Jul–Sep 2023214.87+22.9%23.21+14.8%2.3922 Nov 2023
Q1 FY24Apr–Jun 2023195.02+18.0%20.62−2.0%2.1311 Aug 2023
Q4 FY23Jan–Mar 2023173.04+6.7%18.11−10.7%1.8729 May 2023
Q3 FY23Oct–Dec 2022177.47+3.1%20.34−3.3%2.1016 Feb 2023
Q2 FY23Jul–Sep 2022174.84−9.9%20.21−13.4%2.0923 Nov 2022
Q1 FY23Apr–Jun 2022165.28−34.1%21.05−32.5%2.1706 Sep 2022
Q4 FY22Jan–Mar 2022162.19+22.9%20.26+57.5%2.0924 May 2022
Q3 FY22Oct–Dec 2021172.07+19.2%21.03+59.6%2.1710 Feb 2022
Q2 FY22Jul–Sep 2021194.14+61.3%23.34+42.9%2.4104 Nov 2021
Q1 FY22Apr–Jun 2021250.76+363.1%31.21Turned profit3.2212 Aug 2021
Q4 FY21Jan–Mar 2021131.93+61.7%12.87+172.5%1.3305 Jun 2021
Q3 FY21Oct–Dec 2020144.41+47.7%13.18+87.8%1.6909 Feb 2021
Q2 FY21Jul–Sep 2020120.35+39.9%16.33+279.5%2.1017 Nov 2020
Q1 FY21Apr–Jun 202054.14−41.4%(3.75)Turned loss(0.48)16 Sep 2020
Q4 FY20Jan–Mar 202081.59−10.9%4.72−21.5%0.6106 Aug 2020
Q3 FY20Oct–Dec 201997.74+11.5%7.02+19.4%0.9014 Feb 2020
Q2 FY20Jul–Sep 201986.03−6.9%4.30−30.4%0.5504 Dec 2019
Q1 FY20Apr–Jun 201992.39+17.7%6.81+73.2%0.8817 Aug 2019
Q4 FY19Jan–Mar 201991.55—6.01—0.7712 Jun 2019
Q3 FY19Oct–Dec 201887.65—5.88—0.7614 Feb 2019
Q2 FY19Jul–Sep 201892.42—6.19—0.7920 Nov 2018
Q1 FY19Apr–Jun 201878.49—3.93—0.5118 Aug 2018

45 filings on record for this company.